For Luminal A and Luminal B breast tumors, which do not overexpress HER2, we detected an increase in the group of HER2-low breast cancers from 56.7 for the primary tumor to 64.1% for recurrent disease and to 75.6% for the secondary metastasis. This evidence concerns the gene ERBB2 and breast carcinoma.